Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Economy · News reference
Over six years, U.S. nominal GDP rose 63% while the 30-year Treasury fell 60%. Are investors positioned for a surge in stocks and yields?
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.
Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron earnings due after the bell Wednesday.
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.